Dicerna Pharmaceuticals, Inc. (DRNA) Stock Analysis
DELISTED
What happened to Dicerna Pharmaceuticals, Inc. (DRNA) stock?
Dicerna Pharmaceuticals, Inc. (DRNA) no longer trades on public markets. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Dicerna Pharmaceuticals, Inc. (DRNA). Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company specializing in RNA interference (RNAi) therapeutics. Acquired by Novo Nordisk A/S in December 2021, Dicerna focuses on developing treatments for liver-related diseases using its proprietary GalXC RNAi platform.
Last analyzed: May 10, 2026Dicerna Pharmaceuticals, Inc. (DRNA) Healthcare & Pipeline Overview
More about this archive record
Can I still buy DRNA shares?
No. DRNA stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for DRNA elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before DRNA stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Dicerna Pharmaceuticals, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.